618 related articles for article (PubMed ID: 24189052)
1. Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.
Desimmie BA; Delviks-Frankenberrry KA; Burdick RC; Qi D; Izumi T; Pathak VK
J Mol Biol; 2014 Mar; 426(6):1220-45. PubMed ID: 24189052
[TBL] [Abstract][Full Text] [Related]
2. Stability of APOBEC3F in the Presence of the APOBEC3 Antagonist HIV-1 Vif Increases at the Expense of Co-Expressed APOBEC3H Haplotype I.
Yousefi M; Annan Sudarsan AK; Gaba A; Chelico L
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851677
[TBL] [Abstract][Full Text] [Related]
3. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
Wang J; Shaban NM; Land AM; Brown WL; Harris RS
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
[TBL] [Abstract][Full Text] [Related]
4. Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.
Baig TT; Feng Y; Chelico L
J Virol; 2014 Dec; 88(24):14380-95. PubMed ID: 25275135
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
[TBL] [Abstract][Full Text] [Related]
7. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
Binka M; Ooms M; Steward M; Simon V
J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Vif, APOBEC, and intrinsic immunity.
Goila-Gaur R; Strebel K
Retrovirology; 2008 Jun; 5():51. PubMed ID: 18577210
[TBL] [Abstract][Full Text] [Related]
9. HIV restriction by APOBEC3 in humanized mice.
Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
[TBL] [Abstract][Full Text] [Related]
10. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
Hultquist JF; Lengyel JA; Refsland EW; LaRue RS; Lackey L; Brown WL; Harris RS
J Virol; 2011 Nov; 85(21):11220-34. PubMed ID: 21835787
[TBL] [Abstract][Full Text] [Related]
11. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
12. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
Albin JS; Harris RS
Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
[TBL] [Abstract][Full Text] [Related]
13. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.
Li J; Chen Y; Li M; Carpenter MA; McDougle RM; Luengas EM; Macdonald PJ; Harris RS; Mueller JD
J Mol Biol; 2014 Mar; 426(6):1296-307. PubMed ID: 24361275
[TBL] [Abstract][Full Text] [Related]
15. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
[TBL] [Abstract][Full Text] [Related]
16. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity.
Refsland EW; Hultquist JF; Luengas EM; Ikeda T; Shaban NM; Law EK; Brown WL; Reilly C; Emerman M; Harris RS
PLoS Genet; 2014 Nov; 10(11):e1004761. PubMed ID: 25411794
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.
Chaipan C; Smith JL; Hu WS; Pathak VK
J Virol; 2013 Jan; 87(1):444-53. PubMed ID: 23097438
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
19. A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.
Bennett RP; Salter JD; Smith HC
Trends Mol Med; 2018 May; 24(5):507-520. PubMed ID: 29609878
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
Siu KK; Sultana A; Azimi FC; Lee JE
Nat Commun; 2013; 4():2593. PubMed ID: 24185281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
